A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Condition(s) studied
Investigational drug(s) / intervention(s)
Talquetamab: Talquetamab will be administered subcutaneously.
Prophylaxis A: Prophylaxis A will be administered orally.
Prophylaxis B: Prophylaxis B will be administered orally.
Prophylaxis C: Prophylaxis C will be administered orally.
Prophylaxis D: Prophylaxis D will be administered topically.
Ramantamig: Ramantamig will be administered subcutaneously.
Study summary
The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetamab-related taste changes and to better characterize the signs or symptoms of ramantamig-related taste changes.
Eligibility
Primary outcome measure(s)
- Percentage of Participants With Occurrence of Dysgeusia as Assessed by the Total Waterless Empirical Taste Test (WETT) Testing Score During the Prophylaxis Treatment Phase — Up to 12 months
Dysgeusia is defined as total WETT score of 25th percentile or below according to the Normative WETT-SA53 percentile table. Taste assessment will be performed using taste strips (WETT). Four concentrations (4=lowest concentration, 1=highest concentration) will be used for each taste quality: sweet, sour, salty, bitter, and umami. Each test kit contains 53 taste strips distributed in 4 packs; and each taste strip is numbered (1 through 53). Participants will use each strip sequentially and record the flavor on a score card provided. The test will result in a maximum (that is, best) total score of 53. The score will be graded by a qualified site staff into a normative percentile score using a provided chart. - Percentage of Participants With Occurrence of Severe Dysgeusia During the Prophylaxis Treatment Phase — Up to 12 months
Severe Dysgeusia is defined as a total WETT score of 10th percentile or below according to the normative WETT-SA53 percentile table. Taste assessment will be performed using taste strips (WETT). Four concentrations (4=lowest concentration, 1=highest concentration) will be used for each taste quality: sweet, sour, salty, bitter, and umami. Each test kit contains 53 taste strips distributed in 4 packs; and each taste strip is numbered (1 through 53). Participants will use each strip sequentially and record the flavor on a score card provided. The test will result in a maximum (that is, best) total score of 53. The score will be graded by a qualified site staff into a normative percentile score using a provided chart. - Time to the First Onset of Severe Dysgeusia During the Prophylaxis Treatment Phase — Up to 12 months
Time to the first onset of severe dysgeusia is defined as time from the first dose date of talquetamab to the first onset date of severe dysgeusia according to the total WETT score. For participants without severe dysgeusia, time to the first onset will be censored. Taste assessment will be performed using taste strips (WETT). Four concentrations (4=lowest concentration, 1=highest concentration) will be used for each taste quality: sweet, sour, salty, bitter, and umami. Each test kit contains 53 taste strips distributed in 4 packs; and each taste strip is numbered (1 through 53). Participants will use each strip sequentially and record the flavor on a score card provided. The test will result in a maximum (that is, best) total score of 53. The score will be graded by a qualified site staff into a normative percentile score using a provided chart. - Percentage of Participants Who Report Resolution/Improvement of Dysgeusia During the Prophylaxis Treatment Phase — End of Month 3
Resolution/improvement is defined as 2 potential scenarios: 1) A dysgeusia downgraded to dysgeusia-free, that is (i.e.,) total WETT score of 25th percentile or below at visits prior to the end of month 3 becomes total WETT score above 25th percentile at the end of month 3. 2) Severe dysgeusia downgraded to non-severe dysgeusia, i.e., total WETT score of 10th percentile or below prior to the end of month 3 becomes total WETT score above 10th percentile at the end of month 3. Taste assessment will be performed using taste strips (WETT). Four concentrations will be used for each taste quality: sweet, sour, salty, bitter, \& umami. Each test kit contains 53 taste strips; numbered (1 through 53). Participants will use each strip sequentially and record flavor on score card provided. Test will result in maximum (i.e., best) total score of 53. Score will be graded by qualified staff into normative percentile score using provided chart. - Percentage of Participants Who Report Resolution/Improvement of Dysgeusia During the Prophylaxis Treatment Phase — End of Month 7
Resolution/improvement is defined as 2 potential scenarios: 1) A dysgeusia downgraded to dysgeusia-free, that is (i.e.,) total WETT score of 25th percentile or below at visits prior to the end of month 7 becomes total WETT score above 25th percentile at the end of month 7. 2) Severe dysgeusia downgraded to non-severe dysgeusia, i.e., total WETT score of 10th percentile or below prior to the end of month 7 becomes total WETT score above 10th percentile at the end of month 7. Taste assessment will be performed using taste strips (WETT). Four concentrations will be used for each taste quality: sweet, sour, salty, bitter, \& umami. Each test kit contains 53 taste strips; numbered (1 through 53). Participants will use each strip sequentially and record flavor on score card provided. Test will result in maximum (i.e., best) total score of 53. Score will be graded by qualified staff into normative percentile score using provided chart.
Trial sites (38)
| Facility | City | Region | Status |
|---|---|---|---|
| University of California San Francisco | San Francisco | California | Recruiting |
| Colorado Blood Cancer Institute | Denver | Colorado | Recruiting |
| Yale University School Of Medicine | New Haven | Connecticut | Recruiting |
| Icahn School of Medicine at Mt. Sinai | New York | New York | Recruiting |
| University of Rochester Medical Center | Rochester | New York | Recruiting |
| Duke University Medical Center | Durham | North Carolina | Recruiting |
| University Hospitals Cleveland Medical Center | Cleveland | Ohio | Recruiting |
| Virginia Commonwealth University - Massey Cancer Center | Richmond | Virginia | Recruiting |
| University of Washington | Seattle | Washington | Recruiting |
| IDOR - Regional Brasilia | Brasília | Brazil | Recruiting |
| Fundacao Universidade de Caxias do Sul | Caxias do Sul | Brazil | Recruiting |
| Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer | Curitiba | Brazil | Recruiting |
| IDOR - Regional Bahia | Salvador | Brazil | Recruiting |
| IDOR - Regional Sao Paulo | São Paulo | Brazil | Recruiting |
| Clinica Medica Sao Germano LTDA | São Paulo | Brazil | Recruiting |
| VUMC Amsterdam | Amsterdam | Netherlands | Recruiting |
| Albert Schweitzer Ziekenhuis | Dordrecht | Netherlands | Recruiting |
| Erasmus MC | Rotterdam | Netherlands | Recruiting |
| Hospital Espanol Auxilio Mutuo Auxilio Mutuo Cancer Center | San Juan | Puerto Rico | Recruiting |
| Seoul National University Hospital | Seoul | South Korea | Recruiting |
| The Catholic University of Korea Seoul St Mary s Hospital | Seoul | South Korea | Recruiting |
| Samsung Medical Center | Seoul | South Korea | Recruiting |
| Hosp. Univ. Germans Trias I Pujol | Badalona | Spain | Recruiting |
| Hosp Clinic de Barcelona | Barcelona | Spain | Recruiting |
| Hosp. Univ. Virgen de La Arrixaca | El Palmar | Spain | Recruiting |
| Hosp. de Jerez de La Frontera | Jerez de la Frontera | Spain | Recruiting |
| Hosp. Univ. Ramon Y Cajal | Madrid | Spain | Recruiting |
| Hosp. Univ. 12 de Octubre | Madrid | Spain | Recruiting |
| Hosp. Quiron Madrid Pozuelo | Pozuelo de Alarcón | Spain | Recruiting |
| Hosp Clinico Univ de Salamanca | Salamanca | Spain | Recruiting |
| Belfast City Hospital | Belfast | United Kingdom | Recruiting |
| Colchester Hospital University NHS | Colchester | United Kingdom | Recruiting |
| Eastbourne District General Hospital | Eastbourne | United Kingdom | Recruiting |
| The Clatterbridge Cancer Centre | Liverpool | United Kingdom | Recruiting |
| University College London Hospitals | London | United Kingdom | Recruiting |
| Hammersmith Hospital | London | United Kingdom | Recruiting |
| The Christie NHS Foundation Trust Christie Hospital | Manchester | United Kingdom | Recruiting |
| Newcastle Freeman Hospital | Newcastle upon Tyne | United Kingdom | Completed |
More Janssen Research & Development, LLC trials in Spain
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06500884 on ClinicalTrials.gov ↗ ← All trials in Spain